Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

Also called NCT02130453

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; single masking; primary purpose diagnostic
Phase
Phase 4
Enrolled
  • 161 participants (enrolled count) (from the registry)
Sponsor
M.D. Anderson Cancer Center (from the registry)
Registry
  • NCT NCT02130453
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02130453. Non-randomized; single masking; primary purpose diagnostic. Start 2014-09-30 (actual); primary completion 2024-06-28 (actual). Results posted on 2024-10-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking
Condition
Ischemia
Intervention (Drug)
Regadenoson
Lead sponsor
M.D. Anderson Cancer Center (class: other)
Collaborator
Astellas Scientific & Medical Affairs, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02130453
Content hash
26bd3eff465d4cd858748f7a80f1206eca3fe368cc91d280809764b7a49641ff